Menelri (Ciclosporin)

Ciclosporin, the active ingredient in Menelri, is a calcineurin inhibitor presented as an oral formulation for systemic use. It is employed to reduce immune activity in patients requiring organ transplant maintenance, severe psoriasis, or rheumatoid arthritis, helping to prevent graft rejection and control inflammatory disease.

GNH USA supplies Menelri as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory documentation to support global distribution efficiently.

Ciclosporin is a calcineurin inhibitor used to modulate immune‑mediated conditions.

- Organ transplant rejection: prevents graft rejection by suppressing T‑cell activation. - Severe psoriasis: reduces skin inflammation and plaque formation. - Rheumatoid arthritis: diminishes joint inflammation and disease progression.

Ciclosporin may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Headache: mild to moderate headache. - Hypertension: elevated blood pressure. - Nausea: gastrointestinal upset. - Tremor: fine hand tremors.

Serious or Rare Side Effects: - Nephrotoxicity: impaired kidney function. - Infections: increased susceptibility to bacterial, viral or fungal infections. - Malignancy: higher risk of lymphomas or skin cancers.

When prescribing Ciclosporin, clinicians should consider several safety precautions to minimise risk.

- Monitor renal function: check serum creatinine and glomerular filtration rate regularly. - Assess liver enzymes: perform periodic hepatic function tests. - Check blood pressure: manage hypertension that may develop during therapy. - Review drug interactions: avoid concomitant nephrotoxic or CYP3A4‑inhibiting agents when possible. - Pregnancy and lactation: use only if benefits outweigh potential risks, as safety data are limited. - Store at ambient temperature: keep below 25 °C, in original packaging, protected from moisture.

Ciclosporin interacts with several medicines through metabolic pathways and additive pharmacologic effects.

Major Interactions (Avoid): - Ketoconazole: strong CYP3A4 inhibition markedly increases ciclosporin levels. - Rifampicin: potent CYP3A4 induction reduces ciclosporin exposure, risking graft rejection. - Nephrotoxic drugs (e.g., aminoglycosides): combined use can cause severe kidney injury.

Moderate Interactions (Monitor Closely): - Calcium channel blockers (e.g., diltiazem): may raise ciclosporin concentrations modestly. - Statins (especially simvastatin): increased risk of myopathy; dose adjustment may be needed. - NSAIDs: can enhance renal toxicity when used together.